Medicare announces price cuts for Ozempic and other prescription drugs

A new technology developed by scientists at Northwell Health enables patients with paralysis to move their limbs using neural implants. These chips facilitate a brain-computer interface that reconnects the patient's brain, body, and spinal cord, marking a significant advancement in medical technology.

The Trump administration has announced negotiated prices for 15 drugs under Medicare, which could have saved the program $12 billion last year, reducing spending on these medications by 44%. The list includes popular inhalers like Breo Ellipta and treatments for various conditions including cancer and diabetes.

Medicare has successfully negotiated lower prices for 15 prescription drugs, including significant reductions of up to 71% for Ozempic and Wegovy, following a second round of negotiations with pharmaceutical companies. This initiative aims to enhance affordability for Medicare beneficiaries and improve access to essential medications, including treatments for asthma, breast cancer, and leukemia.

Medicare has announced that starting in 2027, recipients will see reduced prices for 15 prescription drugs, including the widely used weight loss medications Ozempic and Wegovy. This initiative is projected to save taxpayers approximately $12 billion, enhancing affordability for beneficiaries.

A junior college basketball player from Oklahoma died on Tuesday after suffering a head injury during a game in Texas over the weekend, as confirmed by his school. The incident highlights the risks associated with contact sports and the potential for serious injuries that can occur during athletic competitions.

The U.S. government has negotiated lower prices for Ozempic and 14 other popular prescription drugs, resulting in significant cost reductions for Medicare. This initiative is expected to save Medicare billions in prescription-drug spending, enhancing affordability for beneficiaries.

The Centers for Medicare and Medicaid Services announced a significant reduction in prices for 15 prescription drugs, including popular medications Ozempic and Wegovy, aimed at improving access for Medicare beneficiaries. This move is part of ongoing efforts to manage healthcare costs and enhance affordability for patients relying on these treatments.

Novo Nordisk's trials of semaglutide, marketed as Ozempic and Wegovy, have failed to demonstrate any cognitive benefits for individuals with mild cognitive impairment or dementia, marking a significant setback for the company's ambitions to expand the drug's applications beyond obesity and diabetes treatment.